|
Coal Average Selling Price Increase In 4Q22, SIDO managed to record a revenue of IDR 1.2 trillion (+25.0% QoQ; +0.6% YoY) driven by higher sales in the Herbal & Supplement segment (+5.6% YoY) as demand for Tolak Angin increased. Sales in the Pharmaceutical segment also recorded growth in 4Q22, while the F&B segment experienced a decline, with Vitamin C beverage products leading the decline. Additionally, the 4Q22 net profit was recorded at IDR384.3 billion (+39.8% QoQ; -2.8% YoY). Asset Growth In 4Q22, SIDO managed to record a revenue of IDR 1.2 trillion (+25.0% QoQ; +0.6% YoY) driven by higher sales in the Herbal & Supplement segment (+5.6% YoY) as demand for Tolak Angin increased. |
Download full report HERE.
